Today's transplant landscape
Allo-HCT has curative potential, but no new donor sources have been introduced to overcome the challenges of availability, suitability, and deliverability
30% of patients1
no universal
standard of care
- Haploidentical
- Mismatched unrelated
- Umbilical cord blood
Although alternative donor sources provide more options for patients, there may be additional risks associated, such as higher rates of graft-versus-host-disease (GvHD), infections, and non-relapse mortality (NRM).
![Deliverability image](https://omisirge.com/wp-content/themes/wavlowvol/img/deliverability.png)
![Deliverability image](https://omisirge.com/wp-content/themes/wavlowvol/img/deliverability-mobile.png)
Start your patient’s Omisirge treatment journey today
![Find an Omisirge treatment center near you.](https://omisirge.com/wp-content/themes/wavlowvol/img/locations-icon.png)